RESUMO
Maple syrup urine disease (MSUD) is an inherited metabolic disorder caused by a deficiency in branched-chain alpha-ketoacid dehydrogenase complex (BCKAC). The treatment is a standard therapy based on a protein-restricted diet with low branched-chain amino acids (BCAA) content to reduce plasma levels and, consequently, the effects of accumulating their metabolites, mainly in the central nervous system. Although the benefits of dietary therapy for MSUD are undeniable, natural protein restriction may increase the risk of nutritional deficiencies, resulting in a low total antioxidant status that can predispose and contribute to oxidative stress. As MSUD is related to redox and energy imbalance, melatonin can be an important adjuvant treatment. Melatonin directly scavenges the hydroxy radical, peroxyl radical, nitrite anion, and singlet oxygen and indirectly induces antioxidant enzyme production. Therefore, this study assesses the role of melatonin treatment on oxidative stress in brain tissue and behavior parameters of zebrafish (Danio rerio) exposed to two concentrations of leucine-induced MSUD: leucine 2 mM and 5mM; and treated with 100 nM of melatonin. Oxidative stress was assessed through oxidative damage (TBARS, DCF, and sulfhydryl content) and antioxidant enzyme activity (SOD and CAT). Melatonin treatment improved redox imbalance with reduced TBARS levels, increased SOD activity, and normalized CAT activity to baseline. Behavior was analyzed with novel object recognition test. Animals exposed to leucine improved object recognition due to melatonin treatment. With the above, we can suggest that melatonin supplementation can protect neurologic oxidative stress, protecting leucine-induced behavior alterations such as memory impairment.
Assuntos
Doença da Urina de Xarope de Bordo , Melatonina , Animais , Leucina/efeitos adversos , Leucina/metabolismo , Doença da Urina de Xarope de Bordo/metabolismo , Peixe-Zebra/metabolismo , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Melatonina/farmacologia , Melatonina/uso terapêutico , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Estresse Oxidativo , Aminoácidos de Cadeia Ramificada/metabolismo , Superóxido Dismutase/metabolismoRESUMO
AIMS: Safety and tolerability of prolonged supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink (WP-MND) was evaluated in sarcopenic older adults. METHODS: A 13-week double-blinded, randomized, isocaloric placebo-controlled trial (PROVIDE study; n = 380) was extended with a voluntary 13-week open-label extension (OLE). OLE participants were randomized to receive daily 1 or 2 servings of WP-MND (21 g protein, 3 g leucine, 10 µg vitD and 500 mg calcium per serving). Gastro-intestinal tolerability, kidney function and serum levels of calcidiol, parathyroid hormone (PTH) and calcium were evaluated at week 0, 13 and 26. RESULTS AND DISCUSSION: In response to the high daily protein intake (median1.5; IQR: 1.3, 1.7 g/kg BW/day), the estimated glomerular filtration rate (eGFR) increased in the test group during the RCT (p = 0.013). The same trend was observed for those participants with moderate chronic kidney disease. During OLE no eGFR change was observed in any of the groups. Serum calcidiol and calcium reached a plateau after 13-week WP-MND supplementation. As expected, PTH significantly changed in the opposite direction, decreasing during RCT in the test group (T vs C: p < 0.001) and during OLE in former control groups. During RCT, 20/366 participants with normal baseline calcidiol reached levels ≥ 100 nmol/L (T: n = 18; C: n = 2) and 6 developed albumin-corrected calcium levels > 2.55 mmol/L (T: n = 3; C: n = 3), without associated adverse events. CONCLUSION: A 6 months intervention with up to 2 servings of WP-MND did neither result in kidney function deterioration nor symptoms of vitamin D or calcium toxicity. The product was overall well tolerated.
Assuntos
Cálcio , Suplementos Nutricionais , Leucina , Sarcopenia , Proteínas do Soro do Leite , Idoso , Método Duplo-Cego , Feminino , Humanos , Leucina/efeitos adversos , Masculino , Sarcopenia/dietoterapia , Vitamina D , Proteínas do Soro do Leite/efeitos adversosRESUMO
Age-related strength and muscle mass loss is further increased after acute periods of inactivity. To avoid this, resistance training has been proposed as an effective countermeasure, but the additional effect of a protein supplement is not so clear. The aim of this study was to examine the effect of a whey protein supplement enriched with leucine after resistance training on muscle mass and strength gains in a post-hospitalized elderly population. A total of 28 participants were included and allocated to either protein supplementation or placebo supplementation following resistance training for 12 weeks (2 days/week). Physical function (lower and upper body strength, aerobic capacity and the Short Physical Performance Battery (SPPB) test), mini nutritional assessment (MNA) and body composition (Dual X-ray Absorptiometry) were assessed at baseline and after 12 weeks of resistance training. Both groups showed improvements in physical function after the intervention (p < 0.01), but there were no further effects for the protein group (p > 0.05). Muscle mass did not improve after resistance training in either group (p > 0.05). In conclusion, 12 weeks of resistance training are enough to improve physical function in a post-hospitalized elderly population with no further benefits for the protein-supplemented group.
Assuntos
Suplementos Nutricionais , Leucina/administração & dosagem , Contração Muscular , Força Muscular , Músculo Esquelético/fisiopatologia , Treinamento Resistido , Sarcopenia/terapia , Proteínas do Soro do Leite/administração & dosagem , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Suplementos Nutricionais/efeitos adversos , Feminino , Humanos , Leucina/efeitos adversos , Masculino , Estado Nutricional , Valor Nutritivo , Alta do Paciente , Estudos Prospectivos , Recuperação de Função Fisiológica , Treinamento Resistido/efeitos adversos , Sarcopenia/diagnóstico , Sarcopenia/fisiopatologia , Método Simples-Cego , Espanha , Fatores de Tempo , Resultado do Tratamento , Proteínas do Soro do Leite/efeitos adversosRESUMO
BACKGROUND: Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. METHODS: Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. DISCUSSION: The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. TRIAL REGISTRATION: ISRCTN, ISRCTN90094835 . Registered on 18 February 2015.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Suplementos Nutricionais , Leucina/uso terapêutico , Força Muscular/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacos , Perindopril/uso terapêutico , Sarcopenia/tratamento farmacológico , Absorciometria de Fóton , Atividades Cotidianas , Idoso , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Feminino , Avaliação Geriátrica , Humanos , Leucina/efeitos adversos , Masculino , Estudos Multicêntricos como Assunto , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/fisiopatologia , Perindopril/efeitos adversos , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Sarcopenia/diagnóstico por imagem , Sarcopenia/fisiopatologia , Fatores de Tempo , Resultado do Tratamento , Reino UnidoRESUMO
PURPOSE OF REVIEW: The current review highlights the varied effects of medical foods high in leucine (Leu) and devoid of valine (Val) and isoleucine (Ile) in the management of methylmalonic acidemia (MMA) and propionic acidemia and cobalamin C (cblC) deficiency, aiming to advance dietary practices. RECENT FINDINGS: Leu is a key metabolic regulator with a multitude of effects on different organ systems. Recent observational studies have demonstrated that these effects can have unintended consequences in patients with MMA as a result of liberal use of medical foods. The combination of protein restriction and medical food use in MMA and propionic acidemia results in an imbalanced branched-chain amino acid (BCAA) dietary content with a high Leu-to-Val and/or Ile ratio. This leads to decreased plasma levels of Val and Ile and predicts impaired brain uptake of multiple essential amino acids. Decreased transport of methionine (Met) across the blood-brain barrier due to high circulating Leu levels is of particular concern in cblC deficiency in which endogenous Met synthesis is impaired. SUMMARY: Investigations into the optimal composition of medical foods for MMA and propionic acidemia, and potential scenarios in which Leu supplementation may be beneficial are needed. Until then, MMA/propionic acidemia medical foods should be used judiciously in the dietary management of these patients and avoided altogether in cblC deficiency.
Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/dietoterapia , Dieta com Restrição de Proteínas , Alimentos Especializados , Leucina/uso terapêutico , Acidemia Propiônica/dietoterapia , Erros Inatos do Metabolismo dos Aminoácidos/sangue , Animais , Deficiências Nutricionais/sangue , Deficiências Nutricionais/etiologia , Deficiências Nutricionais/prevenção & controle , Dieta com Restrição de Proteínas/efeitos adversos , Alimentos Especializados/efeitos adversos , Homocistinúria/sangue , Homocistinúria/dietoterapia , Humanos , Isoleucina/sangue , Isoleucina/deficiência , Leucina/efeitos adversos , Acidemia Propiônica/sangue , Valina/sangue , Valina/deficiência , Deficiência de Vitamina B 12/sangue , Deficiência de Vitamina B 12/congênito , Deficiência de Vitamina B 12/dietoterapiaRESUMO
BACKGROUND: Frailty is a multifactorial geriatric syndrome characterized by progressive decline in health and associated with decreased muscle mass, strength, and functional capacity. Resistance training (RT) combined with protein or amino acids supplementation has been shown to be promising for mitigating age-related impairments. AIM: To investigate the chronic effects of different strategies of protein and derivatives supplementation in association with RT on selected health-related parameters in pre-frail and frail elderly. METHODS: This is a series of double-blind, randomized, placebo-controlled, parallel-group clinical trials. Volunteers will be divided into nine groups, comprising four different sub-studies evaluating the effects of: isolated leucine supplementation (study 1); protein source (whey vs. soy - study 2); combination of whey protein and creatine (study 3); and sexual dimorphism on the response to protein intake and RT (males vs. females - study 4). Muscle cross-sectional area, fiber cross-sectional area, body composition, lower-limb maximal dynamic and isometric strength, functionality, lipid profile, biochemical parameters, renal function, quality of life, and nutritional status will be assessed before and after a 16-week intervention period. Data will be tested for normality and a mixed-model for repeated measures will be conducted to assess within- and between-group effects of the intervention on the dependent variables. Confidence intervals (95%), effect sizes, and relative changes will also be determined, with significance set at p < 0.05.
Assuntos
Envelhecimento , Proteínas Alimentares/uso terapêutico , Suplementos Nutricionais , Fenômenos Fisiológicos da Nutrição do Idoso , Músculo Esquelético/fisiologia , Treinamento Resistido , Sarcopenia/prevenção & controle , Idoso , Terapia Combinada , Proteínas Alimentares/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Feminino , Idoso Fragilizado , Fragilidade/etiologia , Fragilidade/prevenção & controle , Humanos , Leucina/efeitos adversos , Leucina/uso terapêutico , Masculino , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/fisiopatologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Projetos de Pesquisa , Sarcopenia/diagnóstico por imagem , Sarcopenia/fisiopatologia , Sarcopenia/terapia , Índice de Gravidade de Doença , Caracteres Sexuais , Proteínas de Soja/efeitos adversos , Proteínas de Soja/uso terapêutico , Ultrassonografia , Proteínas do Soro do Leite/efeitos adversos , Proteínas do Soro do Leite/uso terapêuticoRESUMO
We sought to determine the effects of L-leucine (LEU) or different protein supplements standardized to LEU (~3.0 g/serving) on changes in body composition, strength, and histological attributes in skeletal muscle and adipose tissue. Seventy-five untrained, college-aged males (mean ± standard error of the mean (SE); age = 21 ± 1 years, body mass = 79.2 ± 0.3 kg) were randomly assigned to an isocaloric, lipid-, and organoleptically-matched maltodextrin placebo (PLA, n = 15), LEU (n = 14), whey protein concentrate (WPC, n = 17), whey protein hydrolysate (WPH, n = 14), or soy protein concentrate (SPC, n = 15) group. Participants performed whole-body resistance training three days per week for 12 weeks while consuming supplements twice daily. Skeletal muscle and subcutaneous (SQ) fat biopsies were obtained at baseline (T1) and ~72 h following the last day of training (T39). Tissue samples were analyzed for changes in type I and II fiber cross sectional area (CSA), non-fiber specific satellite cell count, and SQ adipocyte CSA. On average, all supplement groups including PLA exhibited similar training volumes and experienced statistically similar increases in total body skeletal muscle mass determined by dual X-ray absorptiometry (+2.2 kg; time p = 0.024) and type I and II fiber CSA increases (+394 µm² and +927 µm²; time p < 0.001 and 0.024, respectively). Notably, all groups reported increasing Calorie intakes ~600-800 kcal/day from T1 to T39 (time p < 0.001), and all groups consumed at least 1.1 g/kg/day of protein at T1 and 1.3 g/kg/day at T39. There was a training, but no supplementation, effect regarding the reduction in SQ adipocyte CSA (-210 µm²; time p = 0.001). Interestingly, satellite cell counts within the WPC (p < 0.05) and WPH (p < 0.05) groups were greater at T39 relative to T1. In summary, LEU or protein supplementation (standardized to LEU content) does not provide added benefit in increasing whole-body skeletal muscle mass or strength above PLA following 3 months of training in previously untrained college-aged males that increase Calorie intakes with resistance training and consume above the recommended daily intake of protein throughout training. However, whey protein supplementation increases skeletal muscle satellite cell number in this population, and this phenomena may promote more favorable training adaptations over more prolonged periods.
Assuntos
Adiposidade , Proteínas Alimentares/administração & dosagem , Suplementos Nutricionais , Leucina/administração & dosagem , Força Muscular , Hidrolisados de Proteína/administração & dosagem , Músculo Quadríceps/fisiologia , Treinamento Resistido , Proteínas de Soja/administração & dosagem , Gordura Subcutânea/fisiologia , Proteínas do Soro do Leite/administração & dosagem , Absorciometria de Fóton , Alabama , Biópsia , Proteínas Alimentares/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Ingestão de Energia , Humanos , Leucina/efeitos adversos , Masculino , Hidrolisados de Proteína/efeitos adversos , Músculo Quadríceps/citologia , Músculo Quadríceps/diagnóstico por imagem , Proteínas de Soja/efeitos adversos , Gordura Subcutânea/citologia , Gordura Subcutânea/diagnóstico por imagem , Fatores de Tempo , Resultado do Tratamento , Ultrassonografia , Proteínas do Soro do Leite/efeitos adversos , Adulto JovemRESUMO
PURPOSE OF REVIEW: Obesity is an increasing problem and high-protein intake early in life seems to increase later risk of obesity. This review summarizes recent publications in the area including observational and intervention studies and publications on underlying mechanisms. RECENT FINDINGS: Recent observational and randomized controlled trials confirmed that high-protein intake in early life seems to increase early weight gain and the risk of later overweight and obesity. Recent studies have looked at the effect of different sources of protein, and especially high-animal protein intake seems to have an effect on obesity. Specific amino acids, such as leucine, have also been implicated in increasing later obesity risk maybe via specific actions on insulin-like growth factor I. Furthermore, additional underlying mechanisms including epigenetics have been linked to long-term obesogenic programming. Finally, infants with catch-up growth or specific genotypes might be particularly vulnerable to high-protein intake. SUMMARY: Recent studies confirm the associations between high-protein intake during the first 2 years and later obesity. Furthermore, knowledge of the mechanisms involved and the role of different dietary protein sources and amino acids has increased, but intervention studies are needed to confirm the mechanisms. Avoiding high-protein intake in early life holds promise as a preventive strategy for childhood obesity.
Assuntos
Dieta Rica em Proteínas/efeitos adversos , Proteínas Alimentares/efeitos adversos , Crescimento/fisiologia , Fenômenos Fisiológicos da Nutrição do Lactente , Obesidade/etiologia , Adulto , Pré-Escolar , Ingestão de Alimentos/fisiologia , Feminino , Humanos , Lactente , Recém-Nascido , Fator de Crescimento Insulin-Like I/metabolismo , Leucina/efeitos adversos , Masculino , Estudos Observacionais como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de RiscoRESUMO
Leucine supplementation has grown in popularity due to the discovery of its anabolic effects on cell signaling and protein synthesis in muscle. The current recommendation is a minimum intake of 55 mg â kg-1. d-1 Leucine acutely stimulates skeletal muscle anabolism and can overcome the anabolic resistance of aging. The value of chronic leucine ingestion for muscle growth is still unclear. Most of the research into leucine consumption has focused on efficacy. To our knowledge, very few studies have sought to determine the maximum safe level of intake. Limited evidence suggests that intakes of ≤1250 mg â kg-1. d-1 do not appear to have any health consequences other than short-term elevated plasma ammonia concentrations. Similarly, no adverse events have been reported for the leucine metabolite ß-hydroxy-ß-methylbutyrate (HMB), although no studies have tested HMB toxicity in humans. Therefore, future research is needed to evaluate leucine and HMB toxicity in the elderly and in specific health conditions.
Assuntos
Suplementos Nutricionais , Leucina/administração & dosagem , Leucina/farmacologia , Humanos , Leucina/efeitos adversos , Desenvolvimento Muscular/efeitos dos fármacos , Músculo Esquelético/efeitos dos fármacosRESUMO
Leucine, a branched-chain amino acid, has been shown to stimulate muscle protein synthesis and has been suggested to play a role in the prevention of age-related muscle atrophy (sarcopenia). Although leucine supplementation may be beneficial, the efficacious dose of leucine is unknown. Before conducting studies with increased doses of leucine, the Tolerable Upper Intake Level (UL) for leucine needs to be determined. The objective of this review is to describe 2 current studies to determine the UL for leucine in young and elderly men. Initially, in young men we tested the conceptual model of determining the maximum oxidative capacity of an amino acid to be an ideal marker for identifying the UL. Leucine oxidation, measured with the use of l-[1-13C]leucine, increased with increasing leucine intakes and reached a plateau at higher intakes. Two-phase linear regression analysis identified a breakpoint of 550 mg â kg-1 â d-1 (95% CI: 454, 646 mg â kg-1 â d-1), with a simultaneous increase in blood ammonia concentrations above normal values (35 µmol/L). Recently, a similar study was conducted in elderly men (â¼72 y old). A breakpoint in leucine oxidation was observed at 431 mg â kg-1 â d-1 (95% CI: 351, 511 mg â kg-1 â d-1), with blood ammonia concentrations above normal (35 µmol/L) at leucine intakes >550 mg â kg-1 â d-1 Taking the data together, the UL for leucine intake in healthy elderly men could be set at a value similar to young men, at 500 mg â kg-1 â d-1, or â¼35 g/d for an individual weighing 70 kg; or, as a cautious estimate, the leucine UL could also be considered as 351 mg â kg-1 â d-1 (the lower 95% CI), which would be â¼24.5 g/d for an elderly individual weighing 70 kg. These studies to determine the UL for leucine in humans are acute diet studies, and future studies with additional biomarkers and long-term supplementation of leucine will be necessary.
Assuntos
Suplementos Nutricionais , Leucina/administração & dosagem , Leucina/efeitos adversos , Idoso , Relação Dose-Resposta a Droga , Humanos , MasculinoRESUMO
On the basis of research presented during the 9th Amino Acid Assessment Workshop, a No Observed Adverse Effect Level (NOAEL) for diet-added arginine (added mostly in the form of dietary supplements) of 30 g/d and an upper limit of safe intake (ULSI) for diet-added tryptophan (added mostly in the form of dietary supplements) of 4.5 g/d have been proposed. Both recommendations apply to healthy young adults. The total dietary leucine ULSI proposed for elderly individuals is 500 mg · kg-1 · d-1 All 3 recommendations are relevant only to high-quality amino acid-containing products with specifications corresponding to those listed in the US Pharmacopeia Because the above amino acids are extensively utilized as dietary supplements for various real or perceived benefits, such as vasodilation, spermatogenesis, sleep, mood regulation, or muscle recovery, the above safety recommendations will have an important impact on regulatory and nutritional practices.
Assuntos
Arginina/administração & dosagem , Arginina/efeitos adversos , Leucina/administração & dosagem , Leucina/efeitos adversos , Triptofano/administração & dosagem , Triptofano/efeitos adversos , Idoso , Suplementos Nutricionais , Relação Dose-Resposta a Droga , Humanos , Necessidades Nutricionais , Adulto JovemRESUMO
Leucine, a branched-chain amino acid (BCAA), has been shown to stimulate muscle protein synthesis, and thus has been proposed to prevent age-related muscle atrophy (sarcopenia). Therefore, leucine supplementation may have potential benefits in elderly populations to preserve muscle mass. The tolerable upper intake level (UL) for leucine intake in young men has recently been determined to be 500 mg kg(-1) day(-1), and increases in blood ammonia concentrations were seen at intake levels above 500 mg kg(-1) day(-1); the UL for leucine in elderly is unknown. The objective of the current study was to determine the safety of leucine supplementation in healthy elderly men. Six healthy elderly men (72.2 ± 3.5 years) received graded stepwise increases in leucine intakes ranging from 50 to 750 mg kg(-1) day(-1), on eight separate study days. Plasma and urinary biochemical variables, including blood ammonia, and an oral primed-continuous protocol of L-1-(13)C-Leucine was performed. Blood ammonia concentrations above normal values (35 µmol/L) were observed at leucine intakes >550 mg kg(-1) day(-1). Leucine oxidation measured as a F(13)CO2 (rate of label tracer oxidation) increased with increasing leucine intakes and started to plateau after 450 mg kg(-1) day(-1). Two-phased linear regression analysis of the F(13)CO2 data revealed a breakpoint of 431 mg kg(-1) day(-1) (R (2) = 0.73), suggesting that the upper limit to oxidize leucine was reached at that point. Taking the data together the upper limit for leucine intake in healthy elderly could be set similar to young men at 500 mg kg(-1) day(-1) or ~35 g/day for an individual weighing 70 kg.
Assuntos
Amônia , Suplementos Nutricionais , Leucina , Músculo Esquelético/metabolismo , Idoso , Amônia/sangue , Amônia/urina , Humanos , Leucina/administração & dosagem , Leucina/efeitos adversos , Leucina/farmacocinética , MasculinoRESUMO
BACKGROUND: Physical inactivity triggers a rapid loss of muscle mass and function in older adults. Middle-aged adults show few phenotypic signs of aging yet may be more susceptible to inactivity than younger adults. OBJECTIVE: The aim was to determine whether leucine, a stimulator of translation initiation and skeletal muscle protein synthesis (MPS), can protect skeletal muscle health during bed rest. DESIGN: We used a randomized, double-blind, placebo-controlled trial to assess changes in skeletal MPS, cellular signaling, body composition, and skeletal muscle function in middle-aged adults (n = 19; age ± SEM: 52 ± 1 y) in response to leucine supplementation (LEU group: 0.06 g â kg(-1) â meal(-1)) or an alanine control (CON group) during 14 d of bed rest. RESULTS: Bed rest decreased postabsorptive MPS by 30% ± 9% (CON group) and by 10% ± 10% (LEU group) (main effect for time, P < 0.05), but no differences between groups with respect to pre-post changes (group × time interactions) were detected for MPS or cell signaling. Leucine protected knee extensor peak torque (CON compared with LEU group: -15% ± 2% and -7% ± 3%; group × time interaction, P < 0.05) and endurance (CON compared with LEU: -14% ± 3% and -2% ± 4%; group × time interaction, P < 0.05), prevented an increase in body fat percentage (group × time interaction, P < 0.05), and reduced whole-body lean mass loss after 7 d (CON compared with LEU: -1.5 ± 0.3 and -0.8 ± 0.3 kg; group × time interaction, P < 0.05) but not 14 d (CON compared with LEU: -1.5 ± 0.3 and -1.0 ± 0.3 kg) of bed rest. Leucine also maintained muscle quality (peak torque/kg leg lean mass) after 14 d of bed-rest inactivity (CON compared with LEU: -9% ± 2% and +1% ± 3%; group × time interaction, P < 0.05). CONCLUSIONS: Bed rest has a profoundly negative effect on muscle metabolism, mass, and function in middle-aged adults. Leucine supplementation may partially protect muscle health during relatively brief periods of physical inactivity. This trial was registered at clinicaltrials.gov as NCT00968344.
Assuntos
Repouso em Cama/efeitos adversos , Suplementos Nutricionais , Leucina/uso terapêutico , Atrofia Muscular/prevenção & controle , Absorciometria de Fóton , Biópsia por Agulha , Composição Corporal , Isótopos de Carbono , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Teste de Esforço , Feminino , Humanos , Leucina/efeitos adversos , Masculino , Pessoa de Meia-Idade , Desenvolvimento Muscular , Proteínas Musculares/metabolismo , Músculo Esquelético/citologia , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Atrofia Muscular/etiologia , Atrofia Muscular/metabolismo , Atrofia Muscular/patologia , Consumo de Oxigênio , Transdução de Sinais , Imagem Corporal TotalRESUMO
Several studies showed that l-leucine supplementation reduces adiposity when provided before the onset of obesity. We studied rats that were exposed to a high-fat diet (HFD) for 10 weeks before they started to receive l-leucine supplementation. Fat mass was increased in l-leucine-supplemented rats consuming the HFD. Accordingly, l-leucine produced a hypothalamic pattern of gene expression that favors fat accumulation. In conclusion, l-leucine supplementation worsened the adiposity of rats previously exposed to HFD possibly by central mechanisms.
Assuntos
Adiposidade/efeitos dos fármacos , Dieta Hiperlipídica/efeitos adversos , Suplementos Nutricionais , Hipotálamo/metabolismo , Leucina/efeitos adversos , Obesidade/patologia , Animais , Ingestão de Energia , Expressão Gênica , Leucina/administração & dosagem , Masculino , Ratos , Ratos WistarRESUMO
We investigated the underlying mechanisms of L-leucine and L-isoleucine mediated promotion of bladder carcinogenesis using an initiation-promotion model. Rats were administered N-butyl-N-(4-hydroxybutyl) nitrosamine for 4 weeks and then fed AIN-93G basal diet or diet supplemented with L-leucine or L-isoleucine for 8 weeks followed by the basal diet for another 8 weeks. At the end of the experiment, week 20, there was a significant elevation of papillary and nodular (PN) hyperplasia multiplicity in the amino acid groups. L-Leucine and L-isoleucine transporters were up-regulated in PN hyperplasias and/or bladder tumors compared with concomitant normal-appearing bladder urothelium at weeks 12 and/or 20 in all groups. In addition, in normal-appearing bladder urothelium, significantly increased mRNA levels of y+LAT1, LAT2, LAT4, and 4F2hc were observed in the amino acid groups compared with the BBN control group at both weeks 12 and 20, and increased mRNA levels of LAT1 were observed at week 20. Furthermore, up-regulation of TNF-α, c-fos, ß-catenin, p53, p21(Cip1/WAF1), cdk4, cyclin D1 and caspase 3 in the amino acid groups was detected in normal-appearing bladder urothelium. Overall, our results indicate that supplementation with l-leucine or l-isoleucine enhanced growth of bladder urothelial tumors by triggering expression of amino acid transporters and tumorigenesis-associated genes.
Assuntos
Sistemas de Transporte de Aminoácidos/metabolismo , Aminoácidos de Cadeia Ramificada/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Regulação Neoplásica da Expressão Gênica , Proteínas de Neoplasias/metabolismo , Neoplasias da Bexiga Urinária/metabolismo , Urotélio/metabolismo , Sistema y+ de Transporte de Aminoácidos/biossíntese , Sistema y+ de Transporte de Aminoácidos/genética , Sistema y+ de Transporte de Aminoácidos/metabolismo , Sistemas de Transporte de Aminoácidos/biossíntese , Sistemas de Transporte de Aminoácidos/genética , Sistemas de Transporte de Aminoácidos Neutros/biossíntese , Sistemas de Transporte de Aminoácidos Neutros/genética , Sistemas de Transporte de Aminoácidos Neutros/metabolismo , Aminoácidos de Cadeia Ramificada/metabolismo , Animais , Carcinogênese/induzido quimicamente , Carcinogênese/metabolismo , Cadeia Pesada da Proteína-1 Reguladora de Fusão/biossíntese , Cadeia Pesada da Proteína-1 Reguladora de Fusão/genética , Cadeia Pesada da Proteína-1 Reguladora de Fusão/metabolismo , Cadeias Leves da Proteína-1 Reguladora de Fusão/biossíntese , Cadeias Leves da Proteína-1 Reguladora de Fusão/genética , Cadeias Leves da Proteína-1 Reguladora de Fusão/metabolismo , Hiperplasia , Isoleucina/efeitos adversos , Isoleucina/metabolismo , Transportador 1 de Aminoácidos Neutros Grandes/biossíntese , Transportador 1 de Aminoácidos Neutros Grandes/genética , Transportador 1 de Aminoácidos Neutros Grandes/metabolismo , Leucina/efeitos adversos , Leucina/metabolismo , Masculino , Proteínas de Neoplasias/biossíntese , Proteínas de Neoplasias/genética , Distribuição Aleatória , Ratos , Ratos Endogâmicos F344 , Carga Tumoral , Bexiga Urinária/efeitos dos fármacos , Bexiga Urinária/metabolismo , Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/induzido quimicamente , Neoplasias da Bexiga Urinária/patologia , Urotélio/efeitos dos fármacos , Urotélio/patologiaRESUMO
The present study was conducted to identify reliable gene biomarkers for the adverse effects of excessive leucine (Leu) in Sprague-Dawley rats by DNA microarray. It has long been known that the adverse effects of excessive amino acid intake depend on dietary protein levels. Male rats were divided into 12 groups (n=6) and fed for 1 wk a diet containing low (6%), moderate (12%) or high (40%) protein. Different levels of Leu (0, 2, 4, and 8%) were added to the diets. Consumption of diets containing more than 4% Leu in 6% protein resulted in growth retardation and reduced liver weight, whereas the administration of the same dose of Leu with 12% or 40% protein did not affect them. By a process of systematic data extraction, 6 candidate gene markers were identified. The liver gene expression data obtained from another experiment with 0, 2, 3, 4, and 8% Leu in a low-protein diet was used to examine the validity of these biomarker candidates with receiver operating characteristic (ROC) curve analysis. All of AUC values of the biomarker candidates were more than 0.700, suggesting the effectiveness of the marker candidates as the indices of Leu excess. The cut-off value for the ROC curve of the gene-marker panel, which was obtained by multiple regression analysis of gene markers, indicated that Leu levels higher than 3% have adverse effects. In conclusion, the gene-marker panel suggested that for male rats dietary Leu supplementation of 2% is the NOAEL dose in low-protein (6%) diets.
Assuntos
Dieta com Restrição de Proteínas , Proteínas Alimentares/administração & dosagem , Suplementos Nutricionais , Ingestão de Energia , Transtornos do Crescimento/etiologia , Leucina/efeitos adversos , Fígado/efeitos dos fármacos , Animais , Área Sob a Curva , Biomarcadores/metabolismo , DNA/análise , Dieta , Relação Dose-Resposta a Droga , Expressão Gênica/efeitos dos fármacos , Marcadores Genéticos , Crescimento/efeitos dos fármacos , Crescimento/genética , Transtornos do Crescimento/genética , Transtornos do Crescimento/metabolismo , Leucina/administração & dosagem , Masculino , Análise em Microsséries , Tamanho do Órgão , Curva ROC , Ratos , Ratos Sprague-Dawley , Valores de Referência , Análise de Regressão , TranscriptomaRESUMO
Leucine is purported to improve athletic performance. Therefore, the BCAA, especially leucine, are popular as dietary supplements among strength-training athletes. There are, however, concerns regarding possible adverse effects of excessive leucine intake. The objective of the current study was to determine the metabolic and adverse effects of the acute ingestion of very high intakes of leucine supplements. Five healthy men (20-35 y) each received graded stepwise increases in leucine intakes of 50, 150, 250, 500, 750, 1000, and 1250 mg · kg(-1) · d(-1) corresponding to the Estimated Average Requirement, and Estimated Average Requirement ×3, ×5, ×10, ×15, ×20, and ×25 to a total of 29 studies. The graded stepwise approach was used rather than a randomization of leucine intake to minimize the possibility of severe adverse effects. Participants were given a maintenance diet for 2 d prior to each leucine level containing 1 g · kg(-1) · d(-1) of protein and 1.7× measured the resting metabolic rate. Leucine oxidation was determined using L-[1-13C]-leucine and the appearance of (13)CO(2) (calculated as F(13)CO(2)) in breath. A range of markers was used to monitor for adverse effects, including glucose, insulin, alanine aminotransferase, and ammonia. Plasma leucine concentrations significantly increased beyond an intake of 500 mg · kg(-1) · d(-1). The metabolic limit to oxidize leucine was between 550 and 700 mg · kg(-1) · d(-1). An increase in blood ammonia concentrations was observed at leucine intakes >500 mg · kg(-1) · d(-1). There were no changes in liver alanine aminotransferase. Glucose concentrations fell (P < 0.004) but remained within the normal range and without any change in insulin. This study is the first to our knowledge to directly estimate the safe upper limit of leucine intake in humans and raises concerns that intakes >550 mg · kg(-1) · d(-1) or ~39 g/d may be a risk to health. It is important to note that these are acute studies, where each participant was exposed to graded increases in leucine intake. Longer term adaptation was not studied.
Assuntos
Leucina/administração & dosagem , Necessidades Nutricionais , Adulto , Animais , Humanos , Hiperamonemia/etiologia , Leucina/efeitos adversos , Leucina/metabolismo , Masculino , OxirreduçãoRESUMO
BACKGROUND: Leucine has been suggested to improve athletic performance. Therefore, the branched-chain amino acids (BCAAs), especially leucine, are popular as dietary supplements in strength-training athletes; however, the intake of leucine in excess of requirements raises concerns regarding adverse effects. Currently, the tolerable upper intake level (UL) for leucine is unknown. OBJECTIVE: The objective of the current study was to determine the UL for leucine in adult men under acute dietary conditions. DESIGN: Five healthy adults (20-35 y) each received graded stepwise increases in leucine intakes of 50, 150, 250, 500, 750, 1000, and 1250 mg · kg⻹ · d⻹, which corresponded to the Estimated Average Requirement (EAR) and the EAR ×3, ×5, ×10, ×15, ×20, and ×25 in a total of 29 studies. The UL of leucine was identified by the measurement of plasma and urinary biochemical variables and changes in leucine oxidation by using l-[1-¹³C]-leucine. RESULTS: A significant increase in blood ammonia concentrations above normal values, plasma leucine concentrations, and urinary leucine excretion were observed with leucine intakes >500 mg · kg⻹ · d⻹. The oxidation of l-[1-¹³C]-leucine expressed as label tracer oxidation in breath (F¹³CO2), leucine oxidation, and α-ketoisocaproic acid (KIC) oxidation led to different results: a plateau in F¹³CO2 observed after 500 mg · kg⻹ · d⻹, no clear plateau observed in leucine oxidation, and KIC oxidation appearing to plateau after 750 mg · kg⻹ · d⻹. CONCLUSION: On the basis of plasma and urinary variables, the UL for leucine in healthy adult men can be suggested at 500 mg · kg⻹ · d⻹ or ~35 g/d as a cautious estimate under acute dietary conditions.
Assuntos
Guias como Assunto , Leucina/efeitos adversos , Política Nutricional , Adulto , Amônia/sangue , Biomarcadores/sangue , Biomarcadores/química , Biomarcadores/metabolismo , Testes Respiratórios , Isótopos de Carbono , Suplementos Nutricionais/efeitos adversos , Humanos , Cetoácidos/metabolismo , Cinética , Leucina/administração & dosagem , Leucina/metabolismo , Masculino , Modelos Biológicos , Oxirredução , Substâncias para Melhoria do Desempenho/administração & dosagem , Substâncias para Melhoria do Desempenho/efeitos adversos , Substâncias para Melhoria do Desempenho/metabolismo , Adulto JovemRESUMO
In the present study, effects of L-leucine and L-isoleucine on rat bladder carcinogenesis were investigated using AIN-93G and MF basal diet. In Experiment 1, N-butyl-N-(4-hydroxybutyl)-nitrosamine was used as an initiator of bladder carcinogenesis. In the AIN-93G diet groups, a significantly higher incidence and multiplicity of bladder tumors, accompanied by decreased final body weight, was observed in the L-leucine-supplemented group and a significantly higher incidence of papillomas and total tumors was observed in the L-isoleucine-supplemented group. In the MF diet groups, the multiplicity of papillary and nodular hyperplasia was significantly increased in the L-isoleucine-supplemented group. Urinary pH values were not affected by supplementing either type of diet with L-leucine or L-isoleucine. In Experiment 2, the amino acid was administered in the basal diets for 2 weeks without initiator. No pathological lesions were observed in the bladder urothelium in any of the groups, and no significant differences in urinary pH values, microcrystals or aggregates were observed between the amino acid-supplemented groups and their respective control groups. In conclusion, long-term treatment with L-leucine or L-isoleucine has a promoting effect on rat bladder carcinogenesis; therefore, their long-term use as a dietary supplement for bladder cancer patients should be avoided until more is known.
Assuntos
Suplementos Nutricionais/efeitos adversos , Isoleucina/efeitos adversos , Leucina/efeitos adversos , Neoplasias da Bexiga Urinária/induzido quimicamente , Animais , Peso Corporal/efeitos dos fármacos , Butilidroxibutilnitrosamina/toxicidade , Dieta , Concentração de Íons de Hidrogênio , Masculino , Papiloma/induzido quimicamente , Papiloma/epidemiologia , Papiloma/patologia , Ratos , Ratos Endogâmicos F344 , Urinálise , Bexiga Urinária/efeitos dos fármacos , Neoplasias da Bexiga Urinária/epidemiologia , Neoplasias da Bexiga Urinária/patologia , Urotélio/efeitos dos fármacosRESUMO
Amino acids function as precursors for de novo protein synthesis. In addition, however, they play a key role as nutritional signals that regulate multiple cellular processes. There is ample in vitro and in vivo evidence showing that muscle tissue responds to increases in amino acid availability via signal transduction pathways that are also regulated by insulin, glucagon, growth hormone, and insulin growth factor 1. The increased amino acid availibility results in the upregulation of mRNA translation, thereby increasing muscle protein synthesis, which, in turn, leads to greater net muscle protein accretion. These findings have been particularly pronounced for the amino acid leucine. Furthermore, leucine has the ability to act as a strong insulin secretagogue. Consequently, it has been suggested that leucine represents an effective pharmaconutrient for the prevention and treatment of sarcopenia and type 2 diabetes. In accordance, recent in vivo studies in humans show that free leucine ingestion can reverse the blunted response of muscle protein synthesis to amino acid/protein intake in the elderly. Although short-term studies suggest that leucine supplementation can stimulate muscle mass accretion in the elderly, there are no long-term nutritional intervention studies to confirm this or the other proposed benefits of leucine as a pharmaconutrient.